Literature DB >> 16163196

Mechanisms and treatment for bone metastases.

Gregory A Clines1, Theresa A Guise.   

Abstract

Alterations in bone architecture and mineral metabolism are common complications of malignancy. Cancers such as breast, prostate, and lung can affect the skeleton either indirectly through the elaboration of factors that act to disrupt normal calcium homeostasis at the level of the kidney and bone; or directly via secondary spread of tumor to bone. Although the pathophysiology of these skeletal complications is diverse, it is clear that the osteoclast and osteoblast are not just bystanders but are active participants in the development and progression of hypercalcemia and bone metastasis. Our understanding of the molecular mechanisms of metastasis leading to tumor cell escape, homing, adhesion, and secondary growth in a hospitable environment are evolving. Treatment modalities aimed at not only reducing tumor burden but altering the skeletal response to tumor have shown benefit. Newer generation bisphosphonates are quite effective in controlling hypercalcemia of malignancy and have been shown to delay progression of skeletal metastases. Clearly, cancer-associated bone morbidity remains a major public health problem. To improve therapy and prevention it is important to understand the pathophysiology of the effects of cancer on bone. This review will detail scientific advances regarding this area.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16163196

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  5 in total

1.  Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.

Authors:  Tatjana I Gabbert; Bodo Hoffmeister; Dieter Felsenberg
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-16       Impact factor: 4.553

2.  Radiofrequency ablation and vertebral augmentation for palliation of painful spinal metastases.

Authors:  Adam N Wallace; Taylor J Greenwood; Jack W Jennings
Journal:  J Neurooncol       Date:  2015-05-29       Impact factor: 4.130

3.  New mechanistic insights of integrin β1 in breast cancer bone colonization.

Authors:  Laure Thibaudeau; Anna V Taubenberger; Christina Theodoropoulos; Boris M Holzapfel; Olivier Ramuz; Melanie Straub; Dietmar W Hutmacher
Journal:  Oncotarget       Date:  2015-01-01

Review 4.  The Role of TGF-β in Bone Metastases.

Authors:  Trupti Trivedi; Gabriel M Pagnotti; Theresa A Guise; Khalid S Mohammad
Journal:  Biomolecules       Date:  2021-11-06

5.  A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.

Authors:  Z Hu; J S Robbins; A Pister; M B Zafar; Z-W Zhang; J Gupta; K J Lee; K Newman; K Neuman; C-O Yun; T Guise; P Seth
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.